CHI's Eighth Annual World Pharmaceutical Congress. Targeting Alzheimer's with novel therapeutics: Part 2.
Yan
Riqiang
R
Cleveland Clinic Lerner Research Institute, OH 44195, USA. yanr@ccf.org
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D002091:Butyrylcholinesterase / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000627:therapeutic use*; D054828:Histamine H3 Antagonists / Q000627:therapeutic use*; D006801:Humans; D020738:Leptin / Q000627:therapeutic use*; D008565:Membrane Proteins / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D016875:tau Proteins / Q000378:metabolism
D002352:Carrier Proteins; D002800:Cholinesterase Inhibitors; D015507:Drugs, Investigational; D054828:Histamine H3 Antagonists; D020738:Leptin; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; C476198:RTN3 protein, human; D014409:Tumor Necrosis Factor-alpha; D016875:tau Proteins; D002091:Butyrylcholinesterase